MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/15/2005 4:45:41 PM
	Read Replies (1) of 1826

Dacogen(TM) (Decitabine) Injection Complete Response Accepted for Review by U.S. FDA Thursday December 15, 4:37 pm ET MINNEAPOLIS and DUBLIN, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MGI PHARMA, INC. (Nasdaq: MOGN - News) and SuperGen, Inc. (Nasdaq: SUPG - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Companies' resubmission as of November 15, 2005 as a complete response to the Approvable Letter for Dacogen(TM) (decitabine) injection for myelodysplastic syndromes (MDS). The resubmission has been classified by the FDA as a Class 2 response, and the FDA has established a user fee goal to review this response by May 15, 2006.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next